The Austrian immunoglobulin in MS (AIMS) study: Final analysis

Multiple Sclerosis

Volumn 6, Issue SUPPL. 2, 2000, Pages

  Strasser Fuchs, S ^a   Fazekas, F ^a   Deisenhammer, F ^a   Nahler, G ^a   Mamoli, B ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Disability; Immunoglobulin; MS; Relapse; Relapsing remitting; Self rating

Indexed keywords

IMMUNOGLOBULIN;

ADOLESCENT; ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DETERIORATION; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG USE; EOSINOPHILIA; FEMALE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RELAPSE; SOCIAL LIFE; TREATMENT OUTCOME;

EID: 0033764433     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245850000602s03     Document Type: Conference Paper

References (12)

1. Intravenous immunoglobulin treatment of neurological autoimmune diseases
2. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders
3. Treatment of inclusion-body myositis with IVIG: A double-blind, placebo-controlled study
4. Treatment of multiple sclerosis with IVIG: Potential effects and methodology of clinical trials
5. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
6. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: Further analysis of the Austrian Immunoglobulin in MS Study
7. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
8. Symposium on a minimal record of disability for multiple sclerosis. Vancouver, Canada, September 11-12, 1983
9. Intravenous immunoglobulin treatment in multiple sclerosis: Effect on relapses
10. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
11. Intravenous immunoglobulin
12. Blood transfusion: Bayer's initiative